Researchers say theirs is first national study with a large population to examine possible link.
All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
Direct-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.
A new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.
Direct-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.
This slide show highlights the top 10 issues we covered this year on managing treatment of patients with HCV infection.
Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.
A new study shows all-oral direct-actin antiviral agents for hepatitis C can provide both short- and long-term economic value.
A test for hepatitis B virus should be done for patients beginning treatment with direct-acting antiviral therapy for their hepatitis C, experts advise.
Targeting people who inject drugs may be the pathway to eradication of the hepatitis C virus (HCV), according to a recent review.